<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863615</url>
  </required_header>
  <id_info>
    <org_study_id>116615</org_study_id>
    <nct_id>NCT01863615</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study for an Isotretinoin</brief_title>
  <official_title>Bioequivalence Study for an Isotretinoin Pharmaceutical Preparation - Capsules. Crossover, Randomized, Single Dose, Two Treatments, Two Periods and Two Sequences With Meal (Breakfast) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The objective of this study was to confirm if two formulations of isotretionin (capsules) are&#xD;
      bioequivalent.&#xD;
&#xD;
      Test product was Oratane® 20 mg (Laboratorios Dermatológicos Darier) and reference product&#xD;
      Roaccutan® 20 mg (Productos Roche). Two capsules administered together were the single&#xD;
      dosage.&#xD;
&#xD;
      The study was prospective, open-label, randomized, crossover, single dose, with 02&#xD;
      treatments, 02 sequences and 02 periods, under fed conditions.&#xD;
&#xD;
      The population was composed of 36 healthy volunteers, male adults between 18-45 years.&#xD;
&#xD;
      The comparative bioavailability of the two formulations was evaluated based in statistical&#xD;
      comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations&#xD;
      in blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 26, 2011</start_date>
  <completion_date type="Actual">September 23, 2011</completion_date>
  <primary_completion_date type="Actual">September 23, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (CMAX) of isotretinoin</measure>
    <time_frame>0.0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours postdosage</time_frame>
    <description>pharmacokinetics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of isotretionin</measure>
    <time_frame>0.0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0, 12.0, 16.0, 24.0, 36.0, 48.0, 60.0, 72.0 and 96.0 hours postdosage</time_frame>
    <description>pharmacokinetics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence od adverse events</measure>
    <time_frame>20 days</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Skin Infections (Acne)</condition>
  <arm_group>
    <arm_group_label>A(reference)/B(test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>initial administration of reference and cross-over to test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B(test)/A(reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>initial administration of test and cross-over to reference</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin 40 mg</intervention_name>
    <description>Roaccutan 2 capsules of 20 mg; reference drug</description>
    <arm_group_label>A(reference)/B(test)</arm_group_label>
    <arm_group_label>B(test)/A(reference)</arm_group_label>
    <other_name>Productos Roche</other_name>
    <other_name>Roaccutan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin 40 mg</intervention_name>
    <description>Oratane 2 capsules of 20 mg; test drug</description>
    <arm_group_label>A(reference)/B(test)</arm_group_label>
    <arm_group_label>B(test)/A(reference)</arm_group_label>
    <other_name>Laboratorios Dermatologicos Darier SA de CV</other_name>
    <other_name>Oratane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male volunteers. Ages between 18 and 45 years old. BMI (Body Mass Index) between 20 to 26&#xD;
        kg/m2. Anti-doping tests negative results. Clinical biochemical test values: Hematic&#xD;
        Biometry, Urine Analysis, Biochemical Profile: (Glucose, Ureic Nitrogen, Urea, Creatinine,&#xD;
        Uric Acid, Cholesterol, Triglycerides, Total Proteins, Albumin, Globulin, Bilirubin (total,&#xD;
        indirect and direct), Alkaline Phosphatase, Lactic Dehydrogenase, AST, ALT, Calcium,&#xD;
        Phosphorus, Sodium, Potassium, Chlorine and Iron), Ac VIH, AgsHB and RPR (luetic test),&#xD;
        must fall within an interval between minimum and maximum values in connection to said tests&#xD;
        accepted values.&#xD;
&#xD;
        Normal Electrocardiogram and Chest X-rays. In exception cases, accepted may be a candidate&#xD;
        for which any previously mentioned test is exceeded regarding considered valid maximum and&#xD;
        minimum accepted normal values, as long as it involves an isolated value and there are no&#xD;
        other manifestations which could allow assuming that a given value is related to a disease&#xD;
        or is remnant of another. These cases must be approved by clinical area and declared as&#xD;
        &quot;Non-clinically significant&quot;.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Electrocardiographic Anomalies; radiological Anti-doping tests positive results, Positive&#xD;
        results regarding RPR; VIH and AgsHB tests. Personal or family history of allergy to&#xD;
        medication in question. Having any kind of allergy, since these persons are in higher risk&#xD;
        of suffering from medicamentous allergy.&#xD;
&#xD;
        Tobacco use. Recreational drug use. Persons undergoing any medical treatment. Existence of&#xD;
        concurrent or intercurrent disease. Existence of justified doubt regarding questionnaire&#xD;
        answers truthfulness. Having participated in bioequivalence or bioavailability studies or&#xD;
        having donated blood 2 months before the study.&#xD;
&#xD;
        Presence of clinically important gastrointestinal diseases or malabsorption history during&#xD;
        the last year.&#xD;
&#xD;
        Presence of a medical condition requiring regular medication (with prescription or&#xD;
        over-the- counter medication) with systemic absorption.&#xD;
&#xD;
        Narcotics or alcohol addiction history requiring treatment. Finally, excluded will be all&#xD;
        those volunteers not meeting that established in Mexican Official Standard&#xD;
        NOM-177-SSA1-1998.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64600</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>Isotretinoin</keyword>
  <keyword>bioequivalence</keyword>
  <keyword>Mexico</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulitis</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

